In the context of bone tumors, a recent study suggested that the dual inhibition of CDK4/6 and of IGF-1R may be a candidate synergistic combination for the clinical application in Ewing sarcoma, since CDK4/6 drug resistance is mediated by the activation of IGF-1R signaling [267]. This evidence concerns the gene CDK4 and Ewing sarcoma.